Targeting Targets for LDL-Lowering Therapy: Lessons from the Collaborative Atorvastatin Diabetes Study (CARDS)
Authors:
Open Access
- 1 March 2009
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (3) , 391-393
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)Clinical Chemistry, 2009
- A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemiasNature Clinical Practice Endocrinology & Metabolism, 2008
- Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2008
- Lipoprotein Management in Patients With Cardiometabolic RiskJACC, 2008
- The Kelowna Diabetes Program: Bridging the Gap Between Testing Guidelines and RealityCanadian Journal of Diabetes, 2008
- Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and WomenJAMA, 2007
- Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable ProblemAnnals of Internal Medicine, 2006
- Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panelJournal of Internal Medicine, 2006
- Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialThe Lancet, 2004
- Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatmentThe Lancet, 2003